Factors associated with the severity of COVID-19 outcomes in people with neuromuscular diseases : Data from the International Neuromuscular COVID-19 Registry
© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology..
BACKGROUND AND PURPOSE: Clinical outcome information on patients with neuromuscular diseases (NMDs) who have been infected with SARS-CoV-2 is limited. The aim of this study was to determine factors associated with the severity of COVID-19 outcomes in people with NMDs.
METHODS: Cases of NMD, of any age, and confirmed/presumptive COVID-19, submitted to the International Neuromuscular COVID-19 Registry up to 31 December 2021, were included. A mutually exclusive ordinal COVID-19 severity scale was defined as follows: (1) no hospitalization; (2) hospitalization without oxygenation; (3) hospitalization with ventilation/oxygenation; and (4) death. Multivariable ordinal logistic regression analyses were used to estimate odds ratios (ORs) for severe outcome, adjusting for age, sex, race/ethnicity, NMD, comorbidities, baseline functional status (modified Rankin scale [mRS]), use of immunosuppressive/immunomodulatory medication, and pandemic calendar period.
RESULTS: Of 315 patients from 13 countries (mean age 50.3 [±17.7] years, 154 [48.9%] female), 175 (55.5%) were not hospitalized, 27 (8.6%) were hospitalized without supplemental oxygen, 91 (28.9%) were hospitalized with ventilation/supplemental oxygen, and 22 (7%) died. Higher odds of severe COVID-19 outcomes were observed for: age ≥50 years (50-64 years: OR 2.4, 95% confidence interval [CI] 1.33-4.31; >64 years: OR 4.16, 95% CI 2.12-8.15; both vs. <50 years); non-White race/ethnicity (OR 1.81, 95% CI 1.07-3.06; vs. White); mRS moderately severe/severe disability (OR 3.02, 95% CI 1.6-5.69; vs. no/slight/moderate disability); history of respiratory dysfunction (OR 3.16, 95% CI 1.79-5.58); obesity (OR 2.24, 95% CI 1.18-4.25); ≥3 comorbidities (OR 3.2, 95% CI 1.76-5.83; vs. ≤2; if comorbidity count used instead of specific comorbidities); glucocorticoid treatment (OR 2.33, 95% CI 1.14-4.78); and Guillain-Barré syndrome (OR 3.1, 95% CI 1.35-7.13; vs. mitochondrial disease).
CONCLUSIONS: Among people with NMDs, there is a differential risk of COVID-19 outcomes according to demographic and clinical characteristics. These findings could be used to develop tailored management strategies and evidence-based recommendations for NMD patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
European journal of neurology - 30(2023), 2 vom: 01. Feb., Seite 399-412 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pizzamiglio, Chiara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 06.01.2023 Date Revised 12.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ene.15613 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348176414 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348176414 | ||
| 003 | DE-627 | ||
| 005 | 20231226035550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ene.15613 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1160.xml |
| 035 | |a (DE-627)NLM348176414 | ||
| 035 | |a (NLM)36303290 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pizzamiglio, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Factors associated with the severity of COVID-19 outcomes in people with neuromuscular diseases |b Data from the International Neuromuscular COVID-19 Registry |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2023 | ||
| 500 | |a Date Revised 12.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. | ||
| 520 | |a BACKGROUND AND PURPOSE: Clinical outcome information on patients with neuromuscular diseases (NMDs) who have been infected with SARS-CoV-2 is limited. The aim of this study was to determine factors associated with the severity of COVID-19 outcomes in people with NMDs | ||
| 520 | |a METHODS: Cases of NMD, of any age, and confirmed/presumptive COVID-19, submitted to the International Neuromuscular COVID-19 Registry up to 31 December 2021, were included. A mutually exclusive ordinal COVID-19 severity scale was defined as follows: (1) no hospitalization; (2) hospitalization without oxygenation; (3) hospitalization with ventilation/oxygenation; and (4) death. Multivariable ordinal logistic regression analyses were used to estimate odds ratios (ORs) for severe outcome, adjusting for age, sex, race/ethnicity, NMD, comorbidities, baseline functional status (modified Rankin scale [mRS]), use of immunosuppressive/immunomodulatory medication, and pandemic calendar period | ||
| 520 | |a RESULTS: Of 315 patients from 13 countries (mean age 50.3 [±17.7] years, 154 [48.9%] female), 175 (55.5%) were not hospitalized, 27 (8.6%) were hospitalized without supplemental oxygen, 91 (28.9%) were hospitalized with ventilation/supplemental oxygen, and 22 (7%) died. Higher odds of severe COVID-19 outcomes were observed for: age ≥50 years (50-64 years: OR 2.4, 95% confidence interval [CI] 1.33-4.31; >64 years: OR 4.16, 95% CI 2.12-8.15; both vs. <50 years); non-White race/ethnicity (OR 1.81, 95% CI 1.07-3.06; vs. White); mRS moderately severe/severe disability (OR 3.02, 95% CI 1.6-5.69; vs. no/slight/moderate disability); history of respiratory dysfunction (OR 3.16, 95% CI 1.79-5.58); obesity (OR 2.24, 95% CI 1.18-4.25); ≥3 comorbidities (OR 3.2, 95% CI 1.76-5.83; vs. ≤2; if comorbidity count used instead of specific comorbidities); glucocorticoid treatment (OR 2.33, 95% CI 1.14-4.78); and Guillain-Barré syndrome (OR 3.1, 95% CI 1.35-7.13; vs. mitochondrial disease) | ||
| 520 | |a CONCLUSIONS: Among people with NMDs, there is a differential risk of COVID-19 outcomes according to demographic and clinical characteristics. These findings could be used to develop tailored management strategies and evidence-based recommendations for NMD patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Guillain-Barré syndrome | |
| 650 | 4 | |a mitochondrial disease | |
| 650 | 4 | |a neuromuscular diseases | |
| 650 | 4 | |a outcome | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Pitceathly, Robert D S |e verfasserin |4 aut | |
| 700 | 1 | |a Lunn, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Brady, Stefen |e verfasserin |4 aut | |
| 700 | 1 | |a De Marchi, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Galan, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Heckmann, Jeannine M |e verfasserin |4 aut | |
| 700 | 1 | |a Horga, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Molnar, Maria J |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveira, Acary S B |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Wladimir B V R |e verfasserin |4 aut | |
| 700 | 1 | |a Primiano, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Ernestina |e verfasserin |4 aut | |
| 700 | 1 | |a Schoser, Benedikt |e verfasserin |4 aut | |
| 700 | 1 | |a Servidei, Serenella |e verfasserin |4 aut | |
| 700 | 1 | |a Sgobbi Souza, Paulo V |e verfasserin |4 aut | |
| 700 | 1 | |a Venugopalan, Vishnu |e verfasserin |4 aut | |
| 700 | 1 | |a Hanna, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Dimachkie, Mazen M |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Pedro M |e verfasserin |4 aut | |
| 700 | 0 | |a Neuromuscular Diseases and COVID-19 Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Albert |e investigator |4 oth | |
| 700 | 1 | |a Elsaddig, Amar |e investigator |4 oth | |
| 700 | 1 | |a Juanatey, Ana |e investigator |4 oth | |
| 700 | 1 | |a Romeiro, Ana |e investigator |4 oth | |
| 700 | 1 | |a Themistocleous, Andreas |e investigator |4 oth | |
| 700 | 1 | |a Kiss-Csenki, Annamaria |e investigator |4 oth | |
| 700 | 1 | |a Guerrero Sola, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Patil, Anuja |e investigator |4 oth | |
| 700 | 1 | |a Duggal, Ashish |e investigator |4 oth | |
| 700 | 1 | |a Gabriel, Carolyn |e investigator |4 oth | |
| 700 | 1 | |a Marshall, Charles |e investigator |4 oth | |
| 700 | 1 | |a Record, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Allen, Claire |e investigator |4 oth | |
| 700 | 1 | |a Bearden, David |e investigator |4 oth | |
| 700 | 1 | |a Rathna Sabapathi, DeviPriya |e investigator |4 oth | |
| 700 | 1 | |a R, Dileep |e investigator |4 oth | |
| 700 | 1 | |a Vecchio, Domizia |e investigator |4 oth | |
| 700 | 1 | |a Newman, Edward |e investigator |4 oth | |
| 700 | 1 | |a Eshun, Edwin |e investigator |4 oth | |
| 700 | 1 | |a Foo, Eng C |e investigator |4 oth | |
| 700 | 1 | |a Bugiardini, Enrico |e investigator |4 oth | |
| 700 | 1 | |a Burke, Georgina |e investigator |4 oth | |
| 700 | 1 | |a Ramdharry, Gita |e investigator |4 oth | |
| 700 | 1 | |a Gorman, Gràinne S |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Guru |e investigator |4 oth | |
| 700 | 1 | |a Sivasathiaseelan, Harri |e investigator |4 oth | |
| 700 | 1 | |a Braga Farias, Igor |e investigator |4 oth | |
| 700 | 1 | |a Smuts, Izelle |e investigator |4 oth | |
| 700 | 1 | |a Holt, James |e investigator |4 oth | |
| 700 | 1 | |a Groothuis, Jan T |e investigator |4 oth | |
| 700 | 1 | |a Pritchard, Jane |e investigator |4 oth | |
| 700 | 1 | |a Wall, Jasmine |e investigator |4 oth | |
| 700 | 1 | |a Gamez, Josep |e investigator |4 oth | |
| 700 | 1 | |a Shakthi, K J S |e investigator |4 oth | |
| 700 | 1 | |a Wannop, Kate |e investigator |4 oth | |
| 700 | 1 | |a Brennan, Kathryn |e investigator |4 oth | |
| 700 | 1 | |a Saavedra, Lillian |e investigator |4 oth | |
| 700 | 1 | |a Clayton, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Househam, Liz |e investigator |4 oth | |
| 700 | 1 | |a Skorupinska, Mariola |e investigator |4 oth | |
| 700 | 1 | |a Laura, Matilde |e investigator |4 oth | |
| 700 | 1 | |a Ciocca, Matteo |e investigator |4 oth | |
| 700 | 1 | |a Zosmer, Maya |e investigator |4 oth | |
| 700 | 1 | |a Dhamne, Megha |e investigator |4 oth | |
| 700 | 1 | |a Mancuso, Michelangelo |e investigator |4 oth | |
| 700 | 1 | |a Janssen, Mirian |e investigator |4 oth | |
| 700 | 1 | |a Musumeci, Olimpia |e investigator |4 oth | |
| 700 | 1 | |a Price, Olivia |e investigator |4 oth | |
| 700 | 1 | |a Chinnery, Patrick F |e investigator |4 oth | |
| 700 | 1 | |a Ambrose, Philip |e investigator |4 oth | |
| 700 | 1 | |a Mehta, Puja R |e investigator |4 oth | |
| 700 | 1 | |a Thomas, Rhys H |e investigator |4 oth | |
| 700 | 1 | |a Horvath, Rita |e investigator |4 oth | |
| 700 | 1 | |a McFarland, Robert |e investigator |4 oth | |
| 700 | 1 | |a Nortley, Ross |e investigator |4 oth | |
| 700 | 1 | |a Paterson, Ross W |e investigator |4 oth | |
| 700 | 1 | |a Geraldes, Ruth |e investigator |4 oth | |
| 700 | 1 | |a Keh, Ryan |e investigator |4 oth | |
| 700 | 1 | |a Neshuku, Saara |e investigator |4 oth | |
| 700 | 1 | |a Sasidharan, Sandhya |e investigator |4 oth | |
| 700 | 1 | |a Menon R, Sarath |e investigator |4 oth | |
| 700 | 1 | |a Raga, Sharika |e investigator |4 oth | |
| 700 | 1 | |a Rinaldi, Simon |e investigator |4 oth | |
| 700 | 1 | |a Yareeda, Sireesha |e investigator |4 oth | |
| 700 | 1 | |a Desai, Soaham |e investigator |4 oth | |
| 700 | 1 | |a Ramaratnam, Sridharan |e investigator |4 oth | |
| 700 | 1 | |a Keddie, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Watson-Fargie, Taylor |e investigator |4 oth | |
| 700 | 1 | |a Evangelista, Teresinha |e investigator |4 oth | |
| 700 | 1 | |a Sansone, Valeria |e investigator |4 oth | |
| 700 | 1 | |a Nesbitt, Victoria |e investigator |4 oth | |
| 700 | 1 | |a Macken, William L |e investigator |4 oth | |
| 700 | 1 | |a Oktay, Yavuz |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of neurology |d 1994 |g 30(2023), 2 vom: 01. Feb., Seite 399-412 |w (DE-627)NLM094480362 |x 1468-1331 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2023 |g number:2 |g day:01 |g month:02 |g pages:399-412 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ene.15613 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2023 |e 2 |b 01 |c 02 |h 399-412 | ||